Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03736486
Other study ID # 2017-5864
Secondary ID
Status Completed
Phase
First received
Last updated
Start date August 24, 2017
Est. completion date December 31, 2018

Study information

Verified date January 2019
Source Sansum Diabetes Research Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The Mil Familias Program is a 10-year initiative to reduce the burden of cardio-metabolic disease among Latino families in the Central Coast of California. The Mil Familias Program involves enrolling 1000 Latino families with at least one member in the family having type 2 diabetes, measuring the 5 determinants of human health: genetics, biology, behavior, psychology and environment, training Latino community health workers ("Especialistas") , creating a Living Information (bio)Bank and planning culturally-relevant interventions.


Description:

The Mil Familias Pilot Study aims to develop, operationalize and refine methods to both recruit and collect data from 100 adult participants pertaining to the 5 determinants of human health: genetics, biology, behavior, psychology and environment. Specially-trained Latino and bilingual community health workers known as "Especialistas" will be used to help gather data and to serve as the participants trustworthy health companion. Over 100 variables of information pertaining to the 5 determinants of human health (as listed above) will be gathered and stored to create a Living Information (bio)Bank particular to Latinos. The ultimate goal of this research is to provide the target population with effective, culturally-relevant interventions that are geared toward population specific needs.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date December 31, 2018
Est. primary completion date December 31, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion criteria:

1. Males or females = 18 years of age at Visit 1 (screening and enrollment).

2. Self-reported Hispanic and/or Latino heritage.

3. Currently residing in Santa Barbara County, California.

4. Established diagnosis of Type 2 diabetes for at least one year prior to enrollment date.

5. Signed and dated written informed consent by the date of Visit 1.

6. Based on the research staff's judgment, subject must have a good understanding, ability, and willingness to adhere to the protocol, including performance of self-monitored data collection during the wearable device portion.

Exclusion Criteria:

1. Diagnosed severe cardiovascular disease, within the 6 months prior to enrollment Visit 1, defined as: previous stroke; decompensated heart failure New York Heart Association class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty.

2. Life expectancy < 2 years.

3. Any active clinically significant disease or disorder, which in the investigator's opinion could interfere with the participation of the trial.

4. Mental incapacity, psychiatric disorder, unwillingness or language barriers precluding comprehension of study activities and informed consent.

5. Participation in other trials involving medication or device within 1 month prior to Visit 1.

6. Known or suspected abuse of alcohol, narcotics, or illicit drugs.

Study Design


Locations

Country Name City State
United States Sansum Diabetes Research Institute Santa Barbara California

Sponsors (2)

Lead Sponsor Collaborator
Sansum Diabetes Research Institute Eli Lilly and Company

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Engagement of a local consortium of partners to implement participant recruitment; data collection, storage, and analysis; healthcare access; and/or intervention measured by the number of major operational partnerships with formal agreements A local consortium of partners will be engaged with formal operational partnerships that include signed agreements and statements of work. These partnerships will include local health clinics and providers, the county, Hispanic/Latino community groups, other non-profit groups involved with the Hispanic/Latino community, and health promoters such as the Young Men's Christian Association (YMCA). 1 year
Other Success measured by the number of health care workers trained, upskilled, and employed to be community health care workers (Especialistas) and the number of participant encounters with a trained health care worker Curricula will be developed, delivered, and evaluated by the number of health workers trained & employed and the number of encounters between participants & trained health workers (Especialistas). Three modules of training curriculum will be developed for Type 2 Diabetes (T2D) Educators, Researchers, and Care Navigators. Training includes T2D clinical aspects, health determinants, diabetes education for Latinos, technology integration into diabetes education, focused diabetes education, research fundamentals, Good Clinical Practice, human subjects protections, participant recruitment, selection & enrollment, clinical data collection, qualitative data collection methods, technology to enhance & facilitate diabetes research, health care sequence, diabetes resources, social and health care resources, health insurance coverage & eligibility, making referrals to resources, sociocultural insight to diabetes care navigation, and technology facilitate access to resources. 1 year
Primary Success (evaluated by Yes/No format) recruiting and establishing a pilot cohort of 100 Latino adults with Type 2 Diabetes and creating data collection methods to describe genetics, biology, behavior, psychology, & environment in Type 2 Diabetes Mil Familias Program Pilot will measure genetic influences by a family medical history & biobank blood samples. Biologic influences will include laboratory blood draw, physical exam with vital signs & waist circumference measurement, and complete medical & medication history with female menopause, pregnancy, & gestational diabetes status. Behavior influences will include sleep, stress, drug abuse, and diabetes self-assessment management questionnaires. Wearable devices will measure physical activity. Psychological influences will include Patient Health Questionnaire-9, Brief Perceived Ethnic Discrimination Questionnaire Community Version, and Short Form Health Survey. Social/environmental influences will include socio-demographics, Brief Acculturation Scale for Hispanics, personal opinions about type 2 diabetes, and questionnaires [Short Assessment of Health Literacy, Trust in Physician, Health Leads Screening Toolkit, and U.S. Household Food Security Survey]. 1 year
Secondary Socio-demographics measured by questionnaire - including age, gender, race/ethnicity, contact information, number in household, income, education, marital status, occupation, insurance status, immigration status, alcohol & tobacco use, and birth place Socio-demographics assessed by questionnaire. Beginning of study - Baseline visit 1
Secondary Self-assessment of diabetes management measured by the American Diabetes Association questionnaire, Participant Self-Assessment of Diabetes Management Participant report and self-assessment of diabetes management by questionnaire Beginning of study - Baseline visit 1
Secondary Food security assessed by U.S. Household Food Security Survey Module: Six-item short form Food security or insecurity assessed by a six-item short form developed by the Economic Research Service, United States Department of Agriculture (USDA), September 2012 Beginning of study - Baseline visit 1
Secondary Social needs screening assessed by the Health Leads Screening Toolkit The Health Leads Screening Tookit (Boston, MA) will be used to determine social needs Beginning of study - Baseline visit 1
Secondary Number of visits to a healthcare provider in the last year and difficulty in traveling to a healthcare provider measured by electronic medical record and interview Number of healthcare visits assessed in medical record review and the difficulty in traveling to the healthcare provider assessed by questionnaire Beginning of study - Baseline visit 1
Secondary Personal opinion regarding type 2 diabetes burden on Latinos measured by 3 questions - why is diabetes common in Latinos, what can be done to prevent diabetes in Latinos, and what things make it difficult to get help with diabetes when it is needed? Questions regarding personal opinions regarding the burden of diabetes on Latinos measured by specific questions Beginning of study - Baseline visit 1
Secondary Support for diabetes care measured by questionnaire adapted from the American Diabetes Association Participant Self-Assessment of Diabetes Management questionnaire How well a participant is supported in diabetes care measured by a questionnaire from the American Diabetes Association (ADA) Participant Self-Assessment of Diabetes Management questionnaire Beginning of study - Baseline visit 1
Secondary Medical history, family medical history, and medication status and history assessed by interview and electronic medical records Medical history, family medical history, and current medications and medication history assessed by interview and electronic medical records Day 1 of Visit 2
Secondary Menopausal status, pregnancy status, and gestational diabetes history for women determined by interview and electronic medical records Menopausal status, pregnancy status, and gestational diabetes history for female participants will be determined by interview and electronic medical records Day 1 of Visit 2
Secondary Measurement by composite physical exam - height, weight, waist circumference, blood pressure, temperature, heart rate & rhythm, and foot examination including questions about neuropathy and retinopathy and dental & eye exams Physical exam with vital signs and questions about neuropathy, retinopathy, dental, and eye exams Day 1 of Visit 2
Secondary Composite lab tests: C-Peptide, C-reactive protein, Complete blood count, Comprehensive metabolic panel, Glutamic Acid Decarboxylase (GAD) antibodies, HbA1c, Insulin autoantibody, Lipid panel, Insulin, and Thyroid function Laboratory blood draw for evaluation of physiological markers related to diabetes Day 1 of Visit 2
Secondary Microalbumin, creatinine, and microalbumin/creatinine ratio measured in a urine sample Urine sample collected for measuring microalbumin, creatinine, and the microalbumin/creatinine ratio Day 1 of Visit 2
Secondary Depression measured by the Patient Health Questionnaire-9 The Patient Health Questionnaire (PHQ)-9 is the Major Depressive Disorder (MDD) module of the full PHQ Day 1 of Visit 2
Secondary Drug abuse measured by the Drug Abuse Screening Test (DAST) - 20 The purpose of the DAST-20 is to provide a brief, simple, practical, but valid method for identifying individuals who are abusing psychoactive drugs; and to yield a quantitative index score of the degree of problems related to drug use and misuse Day 1 of Visit 2
Secondary Physical activity measured by two wearable physical activity monitors for 1 week Participants wear an ActiGraph and Fitbit activity monitors simultaneously for 1 week 1 week
Secondary Acculturation measured by the Brief Acculturation Scale for Hispanics (BASH) BASH is a participant reported questionnaire to measure acculturation Day 1 of Visit 3
Secondary Health literacy measured by the Short Assessment of Health Literacy (SAHL) SAHL is a participant reported questionnaire to measure health literacy Day 1 of Visit 3
Secondary Perceived Ethnic Discrimination measured by the Brief Perceived Ethnic Discrimination Questionnaire - Community version (PEDQ-CV) PEDQ-CV is a participant reported questionnaire to measure perceived ethnic discrimination Day 1 of Visit 3
Secondary Stress measured by the 4 item Perceived Stress Scale (PSS) PSS is a participant reported questionnaire to measure stress Day 1 of Visit 3
Secondary Quality of life measured by the Short Form Health Survey (SF-12) The SF-12 is a participant reported questionnaire to measure quality of life Day 1 of Visit 3
Secondary Sleep quality measured by the Oviedo Sleep Questionnaire (OSQ) The OSQ is a participant reported questionnaire to measure sleep quality Day 1 of Visit 3
Secondary Trust in physician measured by the Trust in Physician (TPS) questionnaire The TPS is a questionnaire and scale to determine trust in the physician Day 1 of Visit 3
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)